✦ LIBER ✦

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

✍ Scribed by Brian I Rini; Bernard Escudier; Piotr Tomczak; Andrey Kaprin; Cezary Szczylik; Thomas E Hutson; M Dror Michaelson; Vera A Gorbunova; Martin E Gore; Igor G Rusakov; Sylvie Negrier; Yen-Chuan Ou; Daniel Castellano; Ho Yeong Lim; Hirotsugu Uemura; Jamal Tarazi; David Cella; Connie Chen; Brad Rosbrook; Sinil Kim; Robert J Motzer

Book ID: 117309382
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 363 KB
Volume: 378
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(11)61613-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Re: Comparative Effectiveness of Axitini

Re: Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial

✍ Patrick A. Kenney; Christopher G. Wood 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Re: Comparative Effectiveness of Axitini

Re: Comparative Effectiveness of Axitinib versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial

✍ Taneja, Samir S. 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 111 KB

Axitinib versus sorafenib as first-line

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

✍ Hutson, Thomas E; Lesovoy, Vladimir; Al-Shukri, Salman; Stus, Viktor P; Lipatov, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 317 KB

Axitinib versus sorafenib as second-line

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

✍ Motzer, Robert J; Escudier, Bernard; Tomczak, Piotr; Hutson, Thomas E; Michaelso 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 316 KB

81 Updated results of the phase 3 AXIS t

81 Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)

✍ B. Escudier; B.I. Rini; T.E. Hutson; M. Gore; S. Oudard; J. Tarazi; B. Rosbrook; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 70 KB

A phase I/II trial of sorafenib and infl

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma

✍ Larkin, J M G; Ferguson, T R; Pickering, L M; Edmonds, K; James, M G; Thomas, K; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 226 KB